Abstract
It has been claimed that early use of statins in acute coronary syndromes (ACS) protects patients against recurrent ischemic events. This protective effect takes place as early as 4 months after treatment initiation in non-ST elevation ACS, as reported in the MIRACL trial. Mechanisms such as improvement in endothelial function and inflammation are possible explanations for this early effect. These findings have been used to propose statins as part of the acute phase therapy. However, the use of statins during hospitalization is an unresolved issue, because there is a lack of evidence regarding the benefit of initiating therapy in the acute phase. Most randomized trials included patients after several days of the index event and did not report in-hospital outcome. This review critically discusses the use of statins in ACS and the level of evidence regarding their beneficial effect in acute phase treatment.
Keywords: Statin therapy, statins, acute coronary syndromes, unstable angina, acute myocardial infarction, acute phase
Current Vascular Pharmacology
Title: Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?
Volume: 5 Issue: 3
Author(s): Luis C.L. Correia
Affiliation:
Keywords: Statin therapy, statins, acute coronary syndromes, unstable angina, acute myocardial infarction, acute phase
Abstract: It has been claimed that early use of statins in acute coronary syndromes (ACS) protects patients against recurrent ischemic events. This protective effect takes place as early as 4 months after treatment initiation in non-ST elevation ACS, as reported in the MIRACL trial. Mechanisms such as improvement in endothelial function and inflammation are possible explanations for this early effect. These findings have been used to propose statins as part of the acute phase therapy. However, the use of statins during hospitalization is an unresolved issue, because there is a lack of evidence regarding the benefit of initiating therapy in the acute phase. Most randomized trials included patients after several days of the index event and did not report in-hospital outcome. This review critically discusses the use of statins in ACS and the level of evidence regarding their beneficial effect in acute phase treatment.
Export Options
About this article
Cite this article as:
Luis C.L. Correia , Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?, Current Vascular Pharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157016107781024127
DOI https://dx.doi.org/10.2174/157016107781024127 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology The Role of Coronary Angioplasty in the Management of Patients with Stable Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets Role of Nitric Oxide in Ischemia and Reperfusion Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Treatment of Foot Disease in Patients with Type 2 Diabetes Mellitus using Human Umbilical Cord Blood Mesenchymal Stem Cells: Response and Correction of Immunological Anomalies
Current Pharmaceutical Design Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Cerebral Ischemia and Angiogenesis
Current Neurovascular Research The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Opioid-induced Cardioprotection
Current Pharmaceutical Design From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
Current Topics in Medicinal Chemistry Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Ranolazine : Effects on Ischemic Heart
Recent Patents on Cardiovascular Drug Discovery